ClinicalTrials.gg
CompletedNCT00638079Updated Apr 19, 2016

Evaluating the Effect of Food on Absorption of Megace ES

A Phase 1 interventional study of Megestrol acetate oral suspension 625 mg/5 mL and Megestrol acetate oral suspension 625 mg/5 mL in Pharmacokinetics, Bioavailability and Absorption, sponsored by Endo Pharmaceuticals. Completed at 1 site in Canada. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-19.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To evaluate the effect of food on the rate and extent of absorption of megestrol acetate 625 mg/5 mL , and determine the safety and tolerability of megestrol acetate 625 mg/5 mL in healthy individuals.

02

Conditions studied

  • Pharmacokinetics
  • Bioavailability
  • Absorption

Keywords

  • Pharmacokinetics
  • Food Effect
  • Bioavailability
  • Megace ES
03

In context

Lead sponsor

Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.

First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ranging from 60-100 kg (132-220 lbs) and ≥18 and ≤32
  • Healthy

Exclusion criteria

Exclusion Criteria:

  • History of or any current medical conditions that could interfere with drug consumption, absorption, distribution, metabolism (eg. CYP450 inducers or inhibitors), or excretion of study drug
  • History of or any current medical conditions that could affect subject safety
  • History of frequent nausea or emesis, regardless of etiology
  • Participation in a clinical drug study during the 30 days preceding the initial dose
  • Significant illness during the 4 weeks preceding study entry
  • Use of any medication, including vitamins/herbal/mineral supplements, during the 7 days preceding the initial dose
  • Refusal or inability to abstain from food 10 hours proceeding and 4 hours following study drug administration, to consume the FDA high fat meal as directed, and to abstain from caffeine- or xanthine-containing beverages entirely during each confinement
  • Any history of or current drug or alcohol abuse
  • Prior alcohol intake exceeding the equivalent of 14 units/week (12 oz beer = 4 oz wine = 1.5 oz shot = 1 unit) on average, or consumption of any alcoholic beverages within 48 hours of study drug administration
  • History of smoking>25 cigarettes/day within 45 days of study drug administration
  • Blood or blood products donated within 30 days prior to study drug administration, or anytime during the study, except as required by this protocol
  • Positive results of urine drug screen, blood alcohol by a Breathalyzer test, surface antigen, hepatitis B surface antibody (unless immunized), or anti-
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    A

    Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal

    Drug: Megestrol acetate oral suspension 625 mg/5 mL

  • Active comparator
    B

    Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast

    Drug: Megestrol acetate oral suspension 625 mg/5 mL

Interventions

  • DrugMegestrol acetate oral suspension 625 mg/5 mL

    Drug page: Megestrol Acetate

    Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal

    Also known as: Megace ES

  • DrugMegestrol acetate oral suspension 625 mg/5 mL

    Drug page: Megestrol Acetate

    Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast

    Also known as: Megace ES

06

What researchers measure

Primary outcomes

  1. Rate and extent of absorption

    Time frame: 120 hours (5 days)

  2. Safety assessed using adverse events (AEs), clinical laboratory results, vital signs, physical examinations, and ECGs.

    Time frame: signing of informed consent to 30 days after last study visit

07

Study locations

1 site
  • SFBC Anapharm
    Montreal (Quebec), H3X 2H9, Canada
08

References and documents

Publications

  • Deschamps B, Musaji N, Gillespie JA. Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension. Int J Nanomedicine. 2009;4:185-92. doi: 10.2147/ijn.s6308. Epub 2009 Sep 10. PubMed 19774117 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
Jun 2006
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
Apr 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00638079
Collaborators
SFBC Anapharm
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
Jun 2006
Primary completion
Jul 2006
Completion
Jul 2006
Last update
Apr 19, 2016

Study contacts

Benoit Deschamps, MD
principal investigator · SFBC Anapharm
Todd Kirby, PhD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion